For example, a subset of patients with non–small cell lung cancer (NSCLC) who have oncogenic mutations in genes, such as EGFR, ALK, or KRAS, typically respond poorly to ICIs (3). This evidence concerns the gene EGFR and non-small cell lung carcinoma.